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Abstract 
The purpose of this study was to assess the effect of three different inoculation routes into mycoplasmal pneumonia 
(MP) in pigs challenged with Mycoplasma hyopneumoniae (M. hyopneumoniae). Thirty six‑week‑old M. hyopneumoniae 
seronegative piglets were randomly assigned to four groups: three challenged groups with experimentally inoculated 
pigs by either the endotracheal (ET; n = 8), intranasal (IN; n = 8) or aerosol (AE; n = 8) routes and one uninfected 
group (Control; n = 6). Blood samples were collected 1 day before challenge and at necropsy, 28 days post‑inocula‑
tion (dpi), to assess seroconversion. Laryngeal swabs were collected at −1, 7, 14, 21 and 28 dpi in order to evaluate 
colonization. At necropsy, lung lesions were scored and lung tissue was collected for histopathological studies and M. 
hyopneumoniae DNA detection. Broncho‑alveolar lavage fluid (BALF) was also obtained to detect M. hyopneumoniae 
DNA, specific IgA antibodies and cytokines. MP was observed in all inoculated groups, but the ET group displayed a 
significantly higher number of animals affected by MP as well as a higher mean lung lesion score. These results were 
paralleled with an earlier seroconversion and upper respiratory tract colonization of M. hyopneumoniae. Additionally, 
in the ET group, higher levels of pro‑inflammatory cytokines and specific IgA antibodies in BALF were found. Under 
the conditions of the present study, MP was reproduced by the three evaluated inoculation routes. Obtained results 
suggest that the ET route is the most effective in order to induce MP in pigs experimentally challenged with M. 
hyopneumoniae.
© 2016 Garcia‑Morante et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any 
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.
org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Mycoplasma hyopneumoniae (M. hyopneumoniae) is 
the causal agent of mycoplasmal pneumonia (MP). MP 
is frequently complicated with other bacteria (enzootic 
pneumonia [EP]) and viruses (porcine respiratory dis-
ease complex [PRDC]), which affect the severity of the 
disease. These chronic respiratory infectious processes 
affect mainly growing and finishing pigs and are sig-
nificant causes of economic losses to swine producers 
throughout the world [1].
M. hyopneumoniae experimental models are essen-
tial for vaccine efficacy assessment. However, optimal 
and reproducible results are not always achieved. In 
fact, variation in pneumonic lesion severity has been 
reported in different experimental M. hyopneumoniae 
challenge systems [2–6], also among animals chal-
lenged with the same isolate and dose [3, 6, 7]. Some 
of the aspects that may influence the M. hyopneumo-
niae infection pattern and the severity of the associated 
lung lesions are the strain, duration of the study, type 
and dose of the inoculum and the inoculation route. 
The intrinsic virulence of M. hyopneumoniae strains has 
been demonstrated to determine the clinical course of 
the infection [6, 8]. Days lapsed between challenge and 
sacrifice (duration of the study) have been related to 
clinical signs appearance and lung lesions development 
[4, 5, 9, 10]. In addition, the host immune response to 
infection is considered a major driver of lung pathology, 
although the underlying inflammatory mechanisms are 
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not yet well understood [10, 11]. With regard to the lat-
ter factor, the use of lung homogenate instead of pure 
culture as inoculum might interfere with the observa-
tion of any specific response to M. hyopneumoniae due 
to the inflammatory response caused by the administra-
tion of foreign antigens [12].
One of the most distinguishing features of experimen-
tal challenge systems is the M. hyopneumoniae inocula-
tion route used. However, its impact on the pathogenesis 
of the experimentally induced M. hyopneumoniae infec-
tion has been poorly investigated. There are four inocula-
tion routes reported in the peer-reviewed literature used 
in swine M. hyopneumoniae challenge models: endotra-
cheal (ET), transtracheal (TT), intranasal (IN) and aero-
sol (AE). Although both intratracheal methods (ET and 
TT) are the most widely used, MP has been induced by 
all models. AE is probably the least extended method, 
despite it is supposed to mimics better the natural con-
ditions of infection [12]. Comparisons between M. hyo-
pneumoniae challenge models using different inoculation 
routes are scarce. Marois et  al. [7] compared the ET, 
the TT and the IN routes, but no differences regarding 
detection and recovery of M. hyopneumoniae, clinical 
signs and lesion scores were evidenced between infection 
conditions.
This last point should be subjected to further investi-
gation. Therefore, the aim of this study was to compare 
three M. hyopneumoniae inoculation routes (ET, IN and 
AE) for their ability to induce MP. The optimum inocula-
tion route was established by studying colonization, clini-
cal, pathological and immunological parameters.
Materials and methods
Animals and housing
Animals were obtained from a herd located in North-
Eastern Spain that was free from M. hyopneumoniae 
and Porcine reproductive and respiratory syndrome virus 
(PRRSV) based on serology and clinical history. For ani-
mal selection, serology (IDEIA™  Mycoplasma hyopneu-
moniae EIA kit; Oxoid, UK) and a nested PCR (nPCR) for 
detection of M. hyopneumoniae DNA [13] was done on 
nasal swabs. Thirty four-week old piglets were selected 
and transported to the experimental facilities of A.M. 
Animalia Bianya S.L. (Girona, Spain). Prior to challenge, 
animals were randomly distributed (Randbetween func-
tion of Excel 2007 software, Microsoft Office®) into four 
groups equalled according to body weight. Challenged 
animals were comingled in the same room whereas the 
control group was placed in a separated room.
Experimental design
At approximately 6  weeks of age, pigs were challenged 
according to the experimental design detailed in Table 1. 
All animals belonging to the challenged groups (n = 24) 
were inoculated with 5  mL of M. hyopneumoniae fresh 
culture on two consecutive days. Two control animals 
received 5 mL of sterile phosphate buffered saline (PBS) 
on two consecutive days by one of the three assessed 
routes (total of n = 6). At 28 days post-inoculation (dpi), 
all pigs were euthanized with an intravenous overdose 
of sodium pentobarbital and subjected to necropsy 
examination.
Study procedure was approved by the Animal 
Experimentation Ethics Committee of the Universitat 
Autònoma de Barcelona (n°= 5796) and of A.M. Anima-
lia Bianya S.L. (n°= 05/15).
Inoculum and inoculation procedures
A fresh culture derived from a M. hyopneumoniae field 
strain was used as the inoculum. This strain was isolated 
in 2010 from a lung of a slaughter-age animal showing 
MP. Inoculum titre was determined by using a limiting 
dilution method. Briefly, ten-fold dilutions of the inoc-
ulum were made and left to grow for 2  weeks at 37  °C. 
Tubes were tested for M. hyopneumoniae by PCR [14] at 
1 and 2 weeks of incubation in order to indirectly evalu-
ate bacterial growth. From the 2nd  week PCR results, 
the final titre was calculated by means of the Reed and 
Muench method [15]. The inoculum titre was 8.25 log10 
PCR50/mL, in which PCR50 represents the limiting 
Table 1 Experimental design
The inoculation took place in 2 consecutive days (0 and 1 dpi). All pigs were euthanized at 4 weeks after the first inoculation (28 dpi).
Group name No. of  
animals
Route of  
inoculation
Inoculum
1st day of challenge (0 dpi) 2nd day of challenge (1 dpi)
Control 2 Endotracheal 5 mL PBS 5 mL PBS
2 Intranasal
2 Aerosol
ET 8 Endotracheal 5 mL M. hyopneumoniae fresh culture 5 mL M. hyopneumoniae fresh culture
IN 8 Intranasal
AE 8 Aerosol
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dilution of the inoculum that is PCR positive in 50% of its 
replicates.
For the ET inoculation, a double catheter (an internal 
with a syringe adapter into an external catheter) (Bas-
tos Medical S.L., Spain) was introduced in the trachea. 
The inoculum was administered with a syringe through 
the internal catheter. For the IN inoculation, a mucosal 
atomization device (MAD Nasal™; Wolfe Tory Medial, 
Inc., USA) attached to a syringe was used to adminis-
trate half of the inoculum volume into each nostril. Ani-
mals included in the AE group, were anaesthetised with a 
combination of 10  mg/kg Ketamine (Imalgene®; Merial, 
France), 0.4  mg/kg Butorfanol (Torbugesic®-SA; Zoe-
tis, USA) and 6  mg/kg of Azaperone (Stresnil®; Esteve, 
Spain) and placed in sternal recumbence. The inoculum 
was administered through an individual mask (Bastos 
Medical S.L., Spain) connected to an aerosol delivery sys-
tem (Boy® SX compressor and LC® Sprint nebulizer; Pari 
GmbH, Germany) with a total output rate of approxi-
mately 600 mg/min and a particle mass median diameter 
of 3.5 µm under a pressure of 1.6 bar.
Clinical evaluation and body weight
After inoculation, pigs were monitored for clinical 
signs on a weekly basis for 4  weeks. The focus of clini-
cal observations was on respiratory signs such as dysp-
noea and coughing. Body weight was registered prior to 
the challenge and at necropsy day. Average daily weight 
gain (ADWG) was calculated according to the following 
formula: body weight at necropsy minus the body weight 
before challenge divided by the days lapsed between 
them.
Collection and samples processing
Blood was collected 1 day before challenge (−1 dpi) and 
at necropsy day (28 dpi). Laryngeal swabs were obtained 
as described previously [16] at −1 dpi and weekly there-
after (7, 14, 21 and 28 dpi). Once in the laboratory, blood 
was centrifuged at 1500  g for 10  min at 4  °C and sera 
were stored at −80 °C until used. Laryngeal swabs were 
resuspended in 1 mL sterile PBS, vortexed and stored at 
−80 °C.
At necropsy (28  dpi), two lung samples were col-
lected from all each animals: one was fixed in 10% neu-
tral buffered formalin and the second one was frozen. 
These samples were used for histopathological studies 
and detection of M. hyopneumoniae DNA respectively. 
Broncho–alveolar lavage fluid (BALF) was collected from 
twelve animals, selecting those three animals showing 
the most severe lung lesions (when present) within each 
group. BALF was left for gross mucus sedimentation and 
supernatant was stored at −80 °C until it was processed. 
These samples were used for M. hyopneumoniae DNA, 
cytokine and specific IgA antibody detection.
Pathological examination
The extension of gross lung lesions compatible with M. 
hyopneumoniae infection (cranio-ventral pulmonary 
consolidation; CVPC) was assessed using the European 
Pharmacopoeia (Ph. Eur., monograph no. 04/2013:2448) 
scoring system. For histopathological studies, formalin-
fixed tissues were processed routinely and embedded in 
paraffin wax. Sections (4 μm) were stained with haema-
toxylin and eosin and examined under light microscope 
for broncho-interstitial pneumonia (BIP). Microscopic 
scoring was performed as previously described [17]. 
Briefly, histopathological lung lesions were graded from 
0 to 4, where 0 to 2 was classified as non-compatible 
with MP and 3 to 4 was considered compatible with MP 
microscopic lung lesions.
Detection of M. hyopneumoniae‑specific antibodies 
in serum and BALF
Sera were tested in duplicate for M. hyopneumoniae anti-
bodies by means of a commercial competitive inhibition 
enzyme-linked immunosorbent assay (IDEIA™ Myco-
plasma hyopneumoniae EIA kit; Oxoid, UK). Samples 
with mean optical density (OD)  <50% of the OD of the 
buffer control were considered positive. Doubtful (OD 
from 50 to 64%) and negative (OD  ≥  65%) OD-values 
were classified as negative in the statistical analysis.
Detection of M. hyopneumoniae specific IgA in BALF 
was performed modifying the Mycoplasma hyopneumo-
niae Antibody Test Kit (BioCheck, UK) with an alkaline 
phosphatase-labelled goat anti-porcine IgA polyclonal 
antibody (Bethyl Laboratories, USA) at 1:5000 dilution as 
secondary antibody. BALF samples were tested undiluted 
and in duplicate. One hundred µL of each sample were 
used in the ELISA assay. The cut-off was established at 
mean OD value of BALF from the control animals plus 
three folds the standard deviation (SD). Values higher 
than the cut-off were considered positive. Values below 
this cut-off were considered negative.
DNA extraction
DNA was extracted from 200 μL of laryngeal swabs sus-
pension or undiluted BALF using BioSprint® 96 DNA 
Blood kit (Qiagen GmbH, Germany) on the BioSprint 
96 workstation (Qiagen GmbH, Germany). Lung tissue 
was disrupted using TissueLyser (Qiagen GmbH, Ger-
many) for DNA extraction. Approximately 1  g of tissue 
was homogenized with 600 µL of PBS into plastic tubes 
containing glass beads. After shaking for 10  min, the 
lung homogenate was centrifuged at 11 000 g for 1 min. 
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DNA was extracted from 200  μL of tissue supernatant 
(MagMAX™ DNA Multi-Sample Kit, Life Technologies, 
USA) according to the manufacturer’s instructions on the 
BioSprint 96 workstation (Qiagen GmbH, Germany). To 
assess potential contamination during the extraction pro-
cedure, a negative control was included using PBS as an 
extraction substrate in each extraction plate.
Real time PCR
A commercial real time M. hyopneumoniae PCR (rt-PCR) 
was performed in laryngeal swabs, BALF and lung tissue 
samples. The assay was performed using VetMAX™-Plus 
qPCR Master Mix (Applied Biosystems, USA) and Vet-
MAX™ M. hyopneumoniae Reagents (Applied Biosys-
tems, USA), according to the manufacturer’s instructions. 
VetMAX™-Plus qPCR Master Mix kit includes Xeno™ 
DNA Control, which serves as an internal positive con-
trol for DNA purification and rt-PCR. Runs were carried 
out in an ABIPRISM® 7500 machine (Applied Biosys-
tems, Singapore). The threshold for the DNA target was 
set at 10% of the average maximum fluorescence value of 
the positive control DNA target. Cycle threshold (Ct) val-
ues equal to or lower than 40 were considered positive.
Evaluation of cytokine responses in BALF
Levels of pro-inflammatory cytokines IL-1β, IL-8, IL-6 
and TNF-α were determined using a commercially avail-
able Porcine Quantikine® ELISA kits (R&D Bio-Scientific 
Pty Ltd, Australia) following manufacturer’s recommen-
dations. BALF samples were tested undiluted. Reactions 
were measured using OD at 450 nm and quantified by the 
use of a standard curve.
Statistical analyses
Statistical analyses were performed using NCSS software 
[18]. Normal distribution of continuous variables was evalu-
ated by the Shapiro–Wilk test. An analysis of variance using 
the Tukey–Kramer test was used for mean comparison of 
continuous variables (lung score, body weight, ADWG, rt-
PCR Ct, cytokine concentrations, percentage of inhibition 
and IgA ELISA OD) among groups. The Chi square or Fis-
cher tests were applied to evaluate the proportion of animals 
showing MP, seroconversion and rt-PCR positive results. In 
order to evaluate the agreement between the rt-PCR results 
in laryngeal swabs and lung tissue, the Cohen’s kappa coef-
ficient (κ) was calculated. P values ≤ 0.05 were considered 
statistically significant, whereas p values > 0.05 and ≤ 0.10 
were considered statistical tendencies.
Results
Negative control pigs were negative for antibodies, clini-
cal signs, DNA and lesions associated to M. hyopneumo-
niae infection throughout the study.
Clinical signs and body weight
Very sporadic and mild coughing was displayed by chal-
lenged pigs from 14  dpi onwards. No other significant 
clinical signs were observed during the experiment. No 
significant differences in mean body weight (at chal-
lenge and at necropsy) neither in ADWG were observed 
among groups (data not shown).
Pathological studies
MP was recognised taking into account three criteria 
concomitantly: (1) Presence of CVPC, based on gross 
evaluation, (2) presence of BIP determined through 
microscopic evaluation (score 3 or 4) and (3) detection of 
M. hyopneumoniae DNA by rt-PCR in lung tissue.
Percentage of animals showing MP and the mean lung 
score within each group are represented in Table 2. MP 
was observed in all inoculated groups. No significant dif-
ferences in the lung lesion  score were observed among 
the IN, AE nor Control groups. In contrast, significant 
differences were obtained regarding the number of ani-
mals showing MP as well as in MP severity between the 
ET and all the other groups (p < 0.05).
Serology and M. hyopneumoniae‑specific IgA in BALF
None of the animals was seropositive 1 day before chal-
lenge (Figure  1). In both IN and AE groups, only one 
animal out of 8 (12.5%) seroconverted at 4  weeks after 
challenge (28 dpi). At that time, five pigs out of 8 (62.5%) 
seroconverted within the ET group (p  <  0.05). The ET 
mean percentage of inhibition was also statically lower 
(p  <  0.01) than all the other groups except for the IN. 
Interestingly, all animals that seroconverted showed MP 
regardless the experimental group.
The cut-off value of the indirect IgA ELISA was estab-
lished at an OD value of 0.21. All BALF samples belong-
ing to the challenged groups (ET, IN and AE) were M. 
hyopneumoniae-IgA positive at 28 dpi at a different lev-
els. The ET group showed a significantly higher (p < 0.01) 
Table 2 Proportion (%) of  animals showing MP and  lung 
lesion score (mean ± SD) at 28 dpi
Different superscripts within a column indicate significant differences between 
groups (p < 0.05).
Group No. of animals 
with MP/Total no. 
of animals (%)
Ph. Eur. score 
including all 
animals per group 
(mean ± SD)
Ph. Eur. score 
of animals 
showing MP 
per group 
(mean ± SD)
Control 0/6 (0.0)a 0.0 (± 0.0)a 0.0 (± 0.0)a
ET 7/8 (87.5)b 9.5 (± 9.8)b 10.8 (± 9.8)b
IN 2/8 (25.0)a 0.9 (± 1.6)a 3.6 (± 0.1)a
AE 3/8 (37.5)a 1.4 (± 2.7)a 3.7 (± 3.3)a
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mean OD value than those of the IN, AE and control 
groups (Figure  2). Although mean specific IgA OD val-
ues in BALF from AE and IN groups were not statistically 
different in comparison with the mean value in Controls, 
a tendency was reported (p ≤ 0.10).
M. hyopneumoniae detection by real time PCR
The percentage of positive animals to M. hyopneumo-
niae rt-PCR and their Ct values (mean ± SD) in laryngeal 
swabs along the study, in lung tissue and BALF within 
each group are represented in Table 3.
All the animals included in the study were negative to 
rt-PCR in laryngeal swabs before challenge. While in the 
ET group M. hyopneumoniae DNA was detected from 
7 dpi onwards, in both IN and AE groups, M. hyopneu-
moniae DNA was not detected until 21  dpi. Indepen-
dently of the group, all animals that became positive in 
a certain time point of the study remained positive until 
the end (28 dpi). The highest percentage of positive ani-
mals was detected at 21 dpi in all groups but except for 
the IN group, in which rt-PCR positive animals appeared 
to increase over the last week (28 dpi). In fact, the maxi-
mum number of positive animals (75%) within a group 
was present in the IN group at 28  dpi. All the animals 
showing MP were rt-PCR positive in laryngeal swabs at 
necropsy day, except two animals belonging to the ET 
group. No significant differences in mean Ct values were 
observed between groups at any time point.
M. hyopneumoniae rt-PCR positive animals in lung tis-
sue were detected in all challenged groups, but the high-
est percentage of positive animals belonged to the ET 
one. All animals with MP were rt-PCR positive in lung 
tissue at necropsy day regardless of the group. However, 
three animals without MP from the IN group were also 
lung rt-PCR positive. From the total of the 15 animals 
that were M. hyopneumoniae positive in lung tissue, 11 
were also positive in laryngeal swabs at the same time 
point of the study (28  dpi), showing both techniques a 
coincidence of 77% (κ = 0.53). Although in the IN group 
5 out of 8 animals (62.5%) were rt-PCR positive, mean 
lung tissue Ct value was significantly (p < 0.05) higher in 
this group compared to the other two challenged groups.
All the BALF samples from the three challenged groups 
(ET, IN and AE) were rt-PCR positive. No significant 
differences in mean Ct values were observed in BALF 
between groups.
Cytokine responses in BALF
Four weeks after infection, IL-6 cytokine was not 
detected in any of the BALF samples tested (data not 
shown). Mean TNF-α (Figure  3A) and IL-8 (Figure  3B) 
cytokine levels were not significantly different between 
groups. Nevertheless, there was a tendency between 
mean levels of TNF-α and IL-8 from ET group and those 
found in Controls (p ≤ 0.10). Remarkably, mean levels of 
IL-1β (p < 0.001) increased significantly in ET-challenged 
pigs in comparison with mean levels found in all other 
groups (Figure 3C).
Discussion
The ability to induce MP in 6-week-old conventional pig-
lets experimentally challenged with M. hyopneumoniae 
using three different inoculation routes was assessed 
in the present study. Lung lesion scores have been pre-
viously reported to be similar between groups of pigs 
experimentally challenged by means of different inocu-
lation routes [7]. However, different M. hyopneumoniae 
infectious doses and necropsy timings were used, diffi-
culting comparisons with the present study, as such fac-
tors are known to influence the infection pattern and MP 
Figure 1 Sera percentage of inhibition (mean ± SD) from 
Control, ET, IN and AE groups 1 day before challenge (−1 dpi) 
and at necropsy (28 dpi). Different superscripts indicate significant 
differences among groups (p < 0.05). Discontinuous line represents 
the seropositivity threshold.
Figure 2 M. hyopneumoniae-IgA antibodies (mean ± SD of OD 
values at 405 nm) in BALF from Control, ET, IN and AE groups 
at 28 dpi. Different superscripts indicate significant differences 
among groups (p < 0.05). Discontinuous line represents the positivity 
threshold.
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severity in pigs [5]. To the best of author’s knowledge, 
this is the first time that the ET, the IN and the AE inocu-
lation routes are compared under the same conditions in 
pigs challenged with M. hyopneumoniae.
The three tested inoculation routes (ET, IN and AE) 
had been already reported to induce MP [6, 7, 12, 19]. In 
agreement with these previous studies and under the set-
tings applied in the present study, all inoculation route 
models reproduced MP. However, the highest percentage 
of animals affected and the most severe lung lesions were 
obtained in the ET inoculated group. These results were 
accompanied by an earlier respiratory tract colonization 
and seroconversion, a higher percentage of rt-PCR posi-
tive animals in lung tissue and an enhanced cellular and 
humoral local immune response. On the other hand, no 
significant differences in clinical signs neither in mean 
body weight at necropsy nor in ADWG were observed 
between groups. The number of animals used, frequency 
of clinical signs observation (only weekly) and duration 
of the study period were probably too limited to observe 
any effect of the inoculation route on coughing and per-
formance parameters.
M. hyopneumoniae is primarily found on the mucosal 
surface of the trachea, bronchi and bronchioli [20], and 
its adherence to the ciliated epithelium is a prerequisite 
for initiation of the infection [21]. Previous studies indi-
cate that tracheo-bronchial swabbing is the most sensi-
tive sampling method for detecting M. hyopneumoniae in 
infected live pigs using nested or real-time PCR assays [7, 
22, 23]. The use of laryngeal swabs to assess M. hyopneu-
moniae infection has been recently reported [16]. Under 
the present conditions and despite being ante-mortem 
and post-mortem samples respectively, 77% of concord-
ance (κ = 0.53) between laryngeal swabs and lung tissue 
for M. hyopneumoniae detection by rt-PCR was found 
at necropsy. In the present report, colonization timing 
differences were found between groups; M. hyopneumo-
niae DNA was detected in the ET group 2 weeks earlier 
(7 dpi) than in the IN and AE groups (21 dpi). Although 
only two out of eight (25%) IN-challenged animals were 
showing MP, laryngeal swabs rt-PCR positive animals 
appeared to increase over the last week (28  dpi) in this 
group, accompanied by quite a high proportion (5 out of 
8) of rt-PCR positive animals in lung tissue at that time. 
It has been reported that M. hyopneumoniae gross lung 
lesions reached their maximum score by 28 dpi [4, 5, 9, 
10]. In consequence, in most experimental infection 
models, pigs are euthanized at this point. Nonetheless, 
it cannot be ruled out that, in AE and/or IN-challenged 
animals, longer study periods would have increased the 
percentage of animals showing MP and its severity.
One limitation of this study was the fact that challenged 
animals were comingled in the same room and transmis-
sion between groups was possible throughout the study. In 
consequence, whether the infection observed in IN and AE 
groups is product of the ET M. hyopneumoniae shedding 
cannot be completely excluded. However, this event would 
be very unlikely since the first evidence of M. hyopneumo-
niae infection was seen at 7 dpi on two animals from the 
ET group. Considering that necropsies were done 3 weeks 
after this first detection, the probability that seroconver-
sion and lung lesions observed in AE and IN-challenged 
animals were due to these two pigs is probably very low.
Among many other factors, development of MP is 
dependent on the number of organisms that colonize the 
respiratory tract, which is likely dependent on cumulated 
infectious doses [1]. Since all groups were challenged 
with the same isolate and dose, the present results point 
out that the inoculation route may have a certain impact 
Figure 3 Levels (mean ± SD) of TNF-α (A), IL-8 (B) and IL-1β (C) 
in BALF of pigs from Control, ET, IN and AE at 28 dpi. Different 
superscripts indicate a significant difference among groups within 
each graph (p < 0.05).
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on the survival and/or infectivity of M. hyopneumoniae, 
which then is reflected on its colonization and in conse-
quence, on the infection outcome. Information regard-
ing how the inoculation route can affect the survival and 
infectivity of M. hyopneumoniae particles is limited. By 
means of the ET route, the inoculum penetration into the 
lower respiratory tract is expected to be higher, which 
might enhance colonization. Although IN and, more 
importantly, the AE inoculation routes mimic better the 
natural infection conditions, the pig’s long and curving 
respiratory tract may represent a major barrier for such 
administrations [24]. Related to this, the size of the aer-
osol particles is relevant, because it influences the time 
until they settle as well as the depth of penetration in the 
respiratory tract upon inhalation [25]. While M. hyopneu-
moniae bacterium mean diameter is 0.20 µm [26], depo-
sition of aerosols in trachea and bronchiole was maximal 
when aerosol droplet size was 2–5  μm [24, 27], a range 
that includes the mean particle size used in the present 
study (3.5 μm). On the contrary, the mucosal atomization 
device used in the IN group sprays a fine mist of parti-
cles of 30–100 μm in size. Although the important vari-
ation between particles sizes derived from both devices, 
in this study no difference in the ability to induce MP was 
evidenced between the IN and AE inoculation condi-
tions. In fact, a higher colonization was recorded in the 
IN group at 28 dpi, meaning that other conditions rather 
than size of particles might influence the M. hyopneumo-
niae deposition in the respiratory tract.
In the current study, a significantly earlier seroconver-
sion and lower percentages of inhibition were found in 
the ET group. The reason for this finding might be due to 
the higher cumulated infectious dose achieved via the ET 
inoculation route, which might imply a faster coloniza-
tion of M. hyopneumoniae and, therefore, a higher expo-
sure to the mucosal immune system. In fact, all animals 
that seroconverted at necropsy had also MP. Indeed, it 
is well known that the concentration of serum antibod-
ies does not correlate with clinical protection against M. 
hyopneumoniae [28, 29]. Nevertheless and similarly to 
serum results, significantly higher specific IgA levels in 
BALF were detected in the ET group. Although specific 
locally secreted IgA after vaccination has been postu-
lated to play a pivotal role in preventing MP development 
[30–33], the results obtained are in accordance to the 
results reported by Djordjevic et al. [28], where IgA anti-
body concentrations achieved after M. hyopneumoniae 
challenge in BALF did not prevent MP development. 
Since the three BALF samples that were taken per group 
belonged to those animals with the highest lung scores 
(when MP was present) and comparisons with those 
animals without lesions within a group could not be per-
formed, BALF results are likely overestimated.
The evaluation of the mucosal immune response was 
further addressed by the analysis of cytokine levels in 
BALF. Cytokine responses in BALF from control ani-
mals were found to be low and within a clinically normal 
range by comparing with previously reported data [6, 10, 
32]. Increased levels of the pro-inflammatory cytokines 
in BALF from M. hyopneumoniae infected pigs [6, 10, 
32, 34, 35] and their relationship with the occurrence of 
pneumonic lesions [3, 36] have already been reported. 
However, the present study aimed to determine whether 
there was a measurable difference in levels of these 
cytokines between pigs challenged by different inocula-
tion routes. Although possible overestimation due to the 
abovementioned reason, IL-1β response was significantly 
more prominent in the ET group than in the IN and AE 
challenged groups 4 weeks after infection. As reported in 
this study, high BALF levels of IL-1β are associated with 
tissue damage in the early stages of the infection [6, 10, 
34]. In contrast, the lower levels of the IL-8 and, more 
importantly, of IL-1β in BALF of the IN and AE inocu-
lated animals in comparison with the ones from the ET 
group, also support the pathological data, since inflam-
mation was significantly lower in these two groups (IN 
and AE).
Under the conditions of this study, ET inoculation 
route was more effective inducing MP 4 weeks after chal-
lenge than the IN or AE ones. ET route is expected to 
apply a greater inoculum volume in pig’s lower respira-
tory tract, achieving greater infectious doses in shorter 
times and promoting an earlier M. hyopneumoniae colo-
nization and immune response against infection, which 
at the end is reflected in a higher incidence and more 
severe MP.
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